Human Genome Sciences, Inc.: Company Profile and SWOT Analysis

Document Sample
Human Genome Sciences, Inc.: Company Profile and SWOT Analysis Powered By Docstoc
					Human Genome Sciences, Inc.

_________________________________________________________________________________



Human Genome Sciences, Inc.                                                   Financial Snapshot

                                                                              Operating Performance
Fast Facts
                                       14200, Shady Grove Road, Rockville,    The company reported revenue of US$157.35 million
Headquarters Address
                                       20850-7464,United States of America    during the fiscal year 2010 (2010). The company's
                                                                              revenue grew at a CAGR of 57.22% during 2006–
Telephone                              + 1 301 3098504
                                                                              2010, with an annual decline of -42.94% over 2009. In
                                                                              2010, the company recorded an operating margin of -
Fax                                    + 1 301 3098512                        121.24%, as against 16.34% in <2009.

Website                                www.hgsi.com
                                                                              Revenue and Margins
Ticker Symbol, Stock Exchange          HGSI, NASDAQ

Number of Employees                    850

Fiscal Year End                        December

Revenue (in US$ million)               157.35




SWOT Analysis

Strengths                              Weaknesses                             Return on Equity

Strong Financial Performance           Dependence on Collaboration Partners   The company recorded a return on equity (ROE) of -
                                                                              39.82% for 2010, as compared to its peers,
Sturdy Research and Development                                               IMMUNOMEDICS, INC (Ticker: IMMU), Amgen Inc.
Activities                                                                    (Ticker: AMGN) and Biogen Idec Inc. (Ticker: BIIB),
                                                                              which recorded ROEs of 90.86%, 19.32% and
World Class Manufacturing Facilities                                          18.63% respectively. The company reported a net
                                                                              profit margin of -121.24% in 2010.
Opportunities                          Threats
                                                                              Return on Equity
Market Potential: Cancer               Industry Consolidation

Rising Healthcare Expenditure in the   Tightening of FDA’s Regulatory
US                                     Oversight

Strategic Partnerships                 Uncertain R&D Outcomes




                                                                              Liquidity Position

                                                                              The company reported a current ratio of 1.89 in 2010,
                                                                              as compared to its peers, IMMUNOMEDICS, INC,
                                                                              Amgen Inc. and Biogen Idec Inc., which recorded
                                                                              current ratios of 7.46, 3.52 and 2.42 respectively. As
                                                                              of December 2010, the company recorded cash and
                                                                              short-term investments of worth US$437.71 million,
                                                                              against US$188.62 million current debt. The company
                                                                              reported a debt to equity ratio of 1.06 in 2010 as
                                                                              compared to its peers, IMMUNOMEDICS, INC,
                                                                              Amgen Inc. and Biogen Idec Inc., which recorded
                                                                              debt to equity ratios of 0.00, 0.56 and 0.22
                                                                              respectively.




___________________________________________________________________________________________

Human Genome Sciences, Inc. - SWOT Profile                                                                            Page 1
Human Genome Sciences, Inc.

_________________________________________________________________________________


TABLE OF CONTENTS

1     Business Analysis ................................................................................................................................... 5
    1.1       Company Overview ................................................................................................................................................5
    1.2       Business Description ..............................................................................................................................................5
    1.3       Major Products and Services .................................................................................................................................6
2     Analysis of Key Performance Indicators ............................................................................................... 7
    2.1       Five Year Snapshot: Overview of Financial and Operational Performance Indicators ..........................................7
    2.2       Key Financial Performance Indicators .................................................................................................................10
      2.2.1       Revenue and Operating Profit .........................................................................................................................10
      2.2.2       Asset, Liabilities and Capex .............................................................................................................................11
      2.2.3       Net Debt vs. Gearing Ratio ..............................................................................................................................12
      2.2.4       Operational Efficiency ......................................................................................................................................13
      2.2.5       Solvency ..........................................................................................................................................................14
    2.3       Competitive Benchmarking ..................................................................................................................................15
      2.3.1       Market Capitalization .......................................................................................................................................15
      2.3.2       Efficiency ..........................................................................................................................................................16
      2.3.3       Capital Expenditure ..........................................................................................................................................17
      2.3.4       Turnover – Inventory and Asset .......................................................................................................................18
3     Mergers & Acquisitions and Partnerships ........................................................................................... 19
    3.1       M&A and Partnerships Strategy ...........................................................................................................................19
4     Recent Developments ........................................................................................................................... 24
5     SWOT Analysis ...................................................................................................................................... 26
    5.1       SWOT Analysis - Overview ..................................................................................................................................26
    5.2       Strengths ..............................................................................................................................................................26
    5.3       Weaknesses .........................................................................................................................................................26
    5.4       Opportunities ........................................................................................................................................................26
    5.5       Threats .................................................................................................................................................................27
6     Human Genome Sciences, Inc. - Company Statement ....................................................................... 29
7     History ...................................
				
DOCUMENT INFO
Description: ICD Research's "Human Genome Sciences, Inc.: Company Profile and SWOT Analysis" contains in depth information and data about the company and its operations. The profile contains a company overview, business description, financial ratios, SWOT analysis, key facts, information on products and services, details of locations and subsidiaries, plus information on key news events affecting the company.
BUY THIS DOCUMENT NOW PRICE: $99 100% MONEY BACK GUARANTEED
PARTNER ICD Research
With emphasis on Insight, Consultancy and Delivery, iCD Research is a full-service, online market research agency. iCD Research is able to take advantage of all of the efficiencies and benefits that the Internet brings to offer proven research methodologies with fast turnaround and accurate results. iCD Research specialises in qualitative research for large finance, media, retail and entertainment clients. Market leaders in online focus groups, iCD Research has unleashed the full scale of the Internet to run focus groups across the globe for its major institutional clients. Utilising its sister organisation, The iD Factor, iCD Research also delivers strong quantitative research, ranging from ongoing consumer confidence studies through to consumer surveys throughout Europe and Asia. With its roots firmly in research, iCD Research doesn’t limit itself to only utilising online methods as the philosophy at the company is to match the methodology to the respondent. Yet the scale and speed of online research give iCD Research a cutting edge that has lead to tremendous, triple-figure percentage growth over the past two years. iCD Research is headquartered in London, with operational offices in the US and Australia to ensure that it is offering an unparalleled 24 hour service to its clients.